Nestin servers as a promising prognostic biomarker in non-small cell lung cancer

Por Liu, Fang, Zhang, Yuan, Lu, Ming, Wang, Cong, Li, Qingbao, Gao, Yongsheng, Mu, Dianbin, Cao, Yan, Li, Miaomiao, Meng, Xiangjiao
Publicado no Am J Transl Res (2017)

Crocin inhibits cell proliferation and enhances cisplatin and pemetrexed chemosensitivity in lung cancer cells

Por Chen, Shuangshuang, Zhao, Shuang, Wang, Xinxing, Zhang, Luo, Jiang, Enze, Gu, Yuan, Shangguan, Anna Junjie, Zhao, Hong, Lv, Tangfeng, Yu, Zhenghong
Publicado no Transl Lung Cancer Res (2015)

How are lung cancer risk perceptions and cigarette smoking related?—testing an accuracy hypothesis

Por Chen, Lei-Shih, Kaphingst, Kimberly A., Tseng, Tung-Sung, Zhao, Shixi
Publicado no Transl Cancer Res (2016)

MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications

Por Zorzetto, Michele, Ferrari, Simona, Saracino, Laura, Inghilleri, Simona, Stella, Giulia M
Publicado no Transl Lung Cancer Res (2012)

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

Por Gao, Hui, Ding, Xin, Wei, Dong, Cheng, Peng, Su, Xiaomei, Liu, Huanyi, Aziz, Fahad, Wang, Daoyuan, Zhang, Tao
Publicado no Transl Lung Cancer Res (2012)

P41. Scedosporium apiospermum mycetoma in a lung cancer patient—case report

Por Alevizopoulos, Nektarios, Laskarakis, Apostolos, Vagdatlis, Theodoros, Ntalapera, Vasiliki, Skoula, Anna, Tegos, Theodoros, Argirakos, Theodoros, Margariti, Charis, Vaslamatzis, Michail
Publicado no Transl Lung Cancer Res (2014)

The “liquid biopsy” in non-small cell lung cancer – not quite ready for prime time use

Por Qin, Angel, Ramnath, Nithya
Publicado no Transl Cancer Res (2016)

Editorial preface to this special issue “Improving the quality and outcomes of lung cancer care: an interdisciplinary approach”

Por Osarogiagbon, Raymond U.
Publicado no Transl Lung Cancer Res (2015)

B-RAF mutation in non-small cell lung cancer: the sleeping beauty is waking up

Por Rolfo, Christian, Caparica, Rafael
Publicado no Transl Lung Cancer Res (2016)

Pembrolizumab as first-line treatment for non-small cell lung cancer—a game changer?

Por Dempke, Wolfram C. M., Fenchel, Klaus
Publicado no Transl Lung Cancer Res (2016)

Preface on “Emerging treatment options for brain metastases from non-small cell lung cancer”

Por Metro, Giulio, Chiari, Rita
Publicado no Transl Lung Cancer Res (2016)

Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer

Por Liam, Chong-Kin
Publicado no Transl Lung Cancer Res (2017)

A strong step forward in maintenance therapy for non-small cell lung cancer treatment

Por Santos, Edgardo S., Mekhail, Tarek
Publicado no Transl Lung Cancer Res (2012)

The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer

Por Di Maio, Massimo, Scagliotti, Giorgio Vittorio
Publicado no Transl Lung Cancer Res (2015)

Incomplete intrapulmonary lymph node retrieval after routine pathologic examination of resected lung cancer

Por Riquet, Marc, Mordant, Pierre
Publicado no Transl Lung Cancer Res (2013)

Professor Helmut H. Popper: the major challenges and potential solutions for future management of lung cancer

Por He, Melanie C.
Publicado no Transl Lung Cancer Res (2015)

Professor Caicun Zhou: a successful step forward for international exchange on combating lung cancer

Por He, Melanie C.
Publicado no Transl Lung Cancer Res (2015)

Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers

Por Chuang, Jody C., Neal, Joel W.
Publicado no Transl Lung Cancer Res (2015)

Nivolumab for refractory metastatic squamous non-small-cell lung cancer: fulfilling an unmet need

Por Marrone, Kristen A., Forde, Patrick M.
Publicado no Transl Lung Cancer Res (2015)

Alectinib in RET-rearranged non-small cell lung cancer—Another progress in precision medicine?

Por Pirker, Robert, Filipits, Martin
Publicado no Transl Lung Cancer Res (2015)